WDR26 and metastatic malignant neoplasm: The physical and functional interaction of TROLL-2 and TROLL-3 with WDR26, as well as its cytoplasmic localization during cancer progression, support the potential use of these factors as markers of cancer progression and as possible predictors of the efficacy for AKT inhibitor-based therapies, and their suitability as therapeutic targets for the development of alternative and, possibly, more effective therapies to treat a broad range of metastatic cancers.